Sensus Healthcare (NASDAQ: SRTS) is one of 113 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Sensus Healthcare to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.
This table compares Sensus Healthcare and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sensus Healthcare Competitors||-38.83%||-90.96%||-18.39%|
This table compares Sensus Healthcare and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sensus Healthcare||$20.59 million||-$3.71 million||-24.57|
|Sensus Healthcare Competitors||$1.44 billion||$104.34 million||-175.73|
Sensus Healthcare’s rivals have higher revenue and earnings than Sensus Healthcare. Sensus Healthcare is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Sensus Healthcare has a beta of -1.29, meaning that its share price is 229% less volatile than the S&P 500. Comparatively, Sensus Healthcare’s rivals have a beta of 0.81, meaning that their average share price is 19% less volatile than the S&P 500.
This is a summary of recent recommendations for Sensus Healthcare and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sensus Healthcare Competitors||641||2361||4481||212||2.55|
Sensus Healthcare currently has a consensus target price of $12.25, indicating a potential upside of 78.05%. As a group, “Surgical & medical instruments” companies have a potential upside of 368.83%. Given Sensus Healthcare’s rivals higher probable upside, analysts plainly believe Sensus Healthcare has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
7.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 41.1% of Sensus Healthcare shares are held by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Sensus Healthcare beats its rivals on 7 of the 13 factors compared.
About Sensus Healthcare
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.